Zurich Cantonal Bank’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Zurich Cantonal Bank’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,501	Closed	-$15K	–	2954
2021 Q3	$15K	Buy	4,501 +29	+0.6%	+$102	﹤0.01%	2800
2021 Q2	$19K	Buy	4,472 +349	+8%	+$1.48K	﹤0.01%	2579
2021 Q1	$21K	Buy	+4,123	New	+$33.3K	﹤0.01%	2524
2019 Q2	–	Sell	-1,415	Closed	-$17K	–	2639
2019 Q1	$17K	Sell	1,415 -1,004	-42%	-$14.8K	﹤0.01%	2459
2018 Q4	$30K	Hold	2,419	–	–	﹤0.01%	2306
2018 Q3	$36K	Hold	2,419	–	–	﹤0.01%	2306
2018 Q2	$41K	Hold	2,419	–	–	﹤0.01%	2240
2018 Q1	$55K	Sell	2,419 -3,249	-57%	-$72.3K	﹤0.01%	2004
2017 Q4	$147K	Buy	5,668 +940	+20%	+$18.9K	﹤0.01%	1369
2017 Q3	$70K	Hold	4,728	–	–	﹤0.01%	1593
2017 Q2	$66K	Hold	4,728	–	–	﹤0.01%	1595
2017 Q1	$81K	Hold	4,728	–	–	﹤0.01%	1506
2016 Q4	$49K	Buy	+4,728	New	+$43.2K	﹤0.01%	1721

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Zurich Cantonal Bank's CNCE Position: Q4 2021 in Review

Zurich Cantonal Bank sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2021, closing a stake of 4,501 shares — an estimated $15K sold.

Zurich Cantonal Bank first reported a position in CNCE in Q4 2016 and held it in 13 quarters. The position peaked at $147K in Q4 2017. 52 funds tracked by Wall St. Rank hold CNCE as of Q4 2021.

Zurich Cantonal Bank reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Zurich Cantonal Bank sold 4,501 Concert Pharmaceuticals, Inc. shares in Q4 2021, an estimated $15K.
Zurich Cantonal Bank first reported a position in Concert Pharmaceuticals, Inc. in Q4 2016 and held it in 13 quarters.
Zurich Cantonal Bank's Concert Pharmaceuticals, Inc. position peaked at $147K in Q4 2017.
52 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2021.

Based on Zurich Cantonal Bank's 13F filing for Q4 2021, filed 1 Feb 2022.